Adjuvant Pancreatic Therapy Guided by MRD

Pancreatic adenocarcinoma (PAAD) is a leading cause of cancer-related deaths worldwide. Although surgical resection can be curative, the 5-year overall survival (OS) rate after resection alone is approximately 20%. Adjuvant chemotherapy can improve survival outcomes in patients with resected PAAD. This study will explore the application of ctDNA MRD in guiding adjuvant therapy in these patients. This prospective, randomized, interventional trial will evaluate a ct-DNA MRD-guided adjuvant therapy strategy in PAAD patients who have undergone radical resection at our institution. Prior to adjuva

Trial Details

NCT ID
NCT06966440
Phase
NA
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • circulating tumor DNA (ctDNA)-based MRD
  • adjuvant chemotherapy regimens
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Capable of providing written informed consent (ICF) and able to understand and agree to comply with the study requirements and assessment schedule
  • Male or female aged 18-75 years at the time of ICF signing.
  • Histologically confirmed pancreatic ductal adenocarcinoma, Stage I-III, and has undergone R0 resection.
  • Time between surgery and randomization ≤ 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →